General Information of This Drug (ID: DM4LSPN)

Drug Name
Ibudilast   DM4LSPN
Synonyms
Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Castleman's disease DISVC11M 4B2Y Approved [1]
------------------------------------------------------------------------------------
5 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alcohol dependence DIS4ZSCO 6C40.2 Phase 2 [2]
Opioid dependence DIS6WEHK 6C43.2Z Phase 2 [2]
Methamphetamine dependence DIS1UU1B 6C46.2 Phase 2 [2]
Multiple sclerosis DISB2WZI 8A40 Phase 2 [3]
Amyotrophic lateral sclerosis DISF7HVM 8B60.0 Phase 2 [4]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Asthma DISW9QNS CA23 Investigative [5]
------------------------------------------------------------------------------------

References

1 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. Brain. 2023 Mar 1;146(3):898-911.